Cabometyx and Metastases to kidney - a phase IV clinical study of FDA data
Metastases to kidney is reported only by a few people who take Cabometyx.
The phase IV clinical study analyzes which people take Cabometyx and have Metastases to kidney. It is created by eHealthMe based on reports of 16,766 people who have side effects while taking Cabometyx from the FDA, and is updated regularly.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
16,766 people reported to have side effects when taking Cabometyx.
Among them, 5 people (0.03%) have Metastases to kidney.
What is Cabometyx?
Cabometyx has active ingredients of cabozantinib s-malate. eHealthMe is studying from 16,768 Cabometyx users for its effectiveness, alternative drugs and more.
What is Metastases to kidney?
Metastases to kidney (cancer spreads to kidney) is found to be associated with 323 drugs and 176 conditions by eHealthMe.
Number of Cabometyx and Metastases to kidney reports submitted per year:
Gender of people who have Metastases to kidney when taking Cabometyx *:
- female: 40 %
- male: 60 %
Age of people who have Metastases to kidney when taking Cabometyx *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 100 %
- 60+: 0.0 %
Common drugs people take besides Cabometyx *:
- Afinitor: 3 people, 60.00%
- Metformin: 1 person, 20.00%
Common side effects people have besides Metastases to kidney *:
- High Blood Pressure: 5 people, 100.00%
- White Blood Cell Count Decreased: 3 people, 60.00%
- Blood Sodium Decreased: 3 people, 60.00%
- Cough: 3 people, 60.00%
- Dry Skin: 3 people, 60.00%
- Haematocrit Decreased: 3 people, 60.00%
- Thrombocytopenia (decrease of platelets in blood): 3 people, 60.00%
- Haemoglobin Decreased: 3 people, 60.00%
- Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 3 people, 60.00%
- Joint Pain: 2 people, 40.00%
Common conditions people have *:
- Renal Cell Carcinoma (a kidney cancer): 3 people, 60.00%
- Renal Neoplasm (kidney tumour): 2 people, 40.00%
- Diabetes: 1 person, 20.00%
* Approximation only. Some reports may have incomplete information.
Do you take Cabometyx and have Metastases to kidney?Check whether Metastases to kidney is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Alternative drugs to, pros and cons of Cabometyx:
- Cabometyx (16,768 reports)
Metastases to kidney treatments and more:
- Metastases to kidney (810 reports)
COVID vaccines that are related to Metastases to kidney:
- Metastases to kidney in Moderna COVID Vaccine
- Metastases to kidney in Pfizer BioNTech Covid Vaccine
- Metastases to kidney in Johnson and Johnson Covid Vaccine
How severe was Metastases to kidney and when was it recovered:
Expand to all the drugs that have ingredients of cabozantinib s-malate:
All the drugs that are associated with Metastases to kidney:
- Metastases to kidney (323 drugs)
All the conditions that are associated with Metastases to kidney:
- Metastases to kidney (176 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on cabozantinib s-malate (the active ingredients of Cabometyx) and Cabometyx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.